Table 4 Prognostic characteristics of tumor in breast cancer patients according to their breast volume (small vs. large).

Clinical tumor size (mm)

23.95 ± 16.46

23.07 ± 17.06

24.80 ± 16.02

Tumor size pathological measurement (mm)

23.80 ± 16.16

24.67 ± 18.53

22.70 ± 12.73

Tumor size (examination) (cm)

≤ 2 cm

58 (56.31%)

35 (61.40%)

23 (50.00%)

> 2 cm

45 (43.68%)

22 (38.60%)

23 (50.00%)

Clinical stage

I

30 (37.97%)

18 (42.85% )

12 (32.43%)

II, III

41 (51.90%)

20 (47.61%)

21 (56.75% )

III

8 (10.13%)

4 (9.52%)

4 (10.81%)

Pathological stage

I

36 (42.35% )

21 (44.68% )

15 (39.47%)

II, III

40 (47.06% )

21 (44.68% )

19 (50%)

IV

9 (10.59% )

5 (10.64% )

4 (10.53%)

Axillary involvement

Negative

48 (58.54%)

26 (57.78%)

22 (59.46%)

Positive

34 (41.46%)

19 (42.22%)

15 (40.54%)

Histological type

Ductal

92 (96.48%)

51 (94.44%)

41 (100%)

Lobulillar

3 (3.16%)

3 (5.56%)

0

Differentiation grade

1, 2

53 (68.83% )

32 (74.42%)

21 (61.76% )

3

24 (31.17% )

11 (25.58% )

13 (38.24% )

Lymphovascular invasion (n = 77)^a

Yes

74 (96.10%)

41 (97.62%)

33 (94.29% )

No

3 (3.9%)

1 (2.38%)

2 (5.71% )

Ki-67 (n = 84)^a

(+)

75 (89.29%)

39 (86.67%)

36 (92.31% )

(−)

9 (10.71%)

6 (13.33%)

3 (7.69% )

Ki-67 (%) (n = 84)^a

27.76 ± 22.3

27.96 ± 24.1

27.17 ± 20.3

ER

(+)

76 (83.52%)

37 (77.00%)

39 (95.1%)

(−)

15 (16.48%)

11 (22.92%)

2 (9.3%)

PR

(+)

71 (78.02%)

36 (75%)

35 (81.4%)

(−)

20 (21.98%)

12 (25%)

8 (18.6%)

Cerb2 (^a)

(+)

24 (28.24%)

11 (24.44%)

13 (32.5% )

(−)

61 (71.76%)

34 (75.56%)

27 (67.5%)

NPI

3.43 ± 1.78

3.34 ± 1.74

3.54 ± 1.84

NPI

< 2

14 (17.07%)

8 (17.78%)

6 (16.22% )

2–2.4

16 (19.52%)

9 (20%)

7 (18.92% )

2.4–3.4

14 (17.07%)

6 (13.33%)

8 (21.62% )

3.4–5.4

17 (20.73%)

14 (31.11%)

3 (8.11% )

> 5.4

21 (25.61%)

8 (17.78%)

13 (35.14% )